Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...
Novartis CEO on the impact of the U.S. election for pharma
Novartis CEO Vas Narasimhan talks to CNBC about the company's latest results and the potential impact of the U.S. election on ...
Novartis Lifts Guidance Again After Key Drugs Help Results
Novartis raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by ...
Swissinfo8d
Novartis CEO: ‘Our strategy is bearing fruit’
Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.
ENDPOINTS NEWS11d
No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment
Novartis CEO Vas Narasimhan assured investors on Tuesday that it takes a careful, systematic approach to M&A after recording ...
Novartis: we are exploring obesity drugs but other areas provide growth for years
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given ...
FiercePharma11d
Novartis' Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time
Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...